title: The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury.
abstract: OBJECTIVE
  The purpose of this study was to investigate the effects of a selective COX-2 inhibitor, FK3311, on warm ischemia-reperfusion injury of the canine small intestine.
  
  
  METHODS
  Ten adult mongrel dogs were used. FK (1 mg/kg) was administered intravenously 15 minutes prior to ischemia and 15 minutes prior to reperfusion in the FK group (n = 5), and only an inert vehicle was injected in the control group (n = 5). The superior mesenteric artery and vein were clamped closed for 2 hours and then unclamped for 12 hours of reperfusion. Arterial and intramucosal pH were measured, and samples were taken for histological examination at 1, 3, 6, and 12 hours after the start of reperfusion. Serum thromboxane B2 and 6-keto-prostaglandin F1 alpha (stable metabolites of TxA2 and PGI2) were measured 30 minutes after reperfusion began.
  
  
  RESULTS
  Arterial and intramucosal pH changes were significantly (p < 0.05) smaller in the FK group than in the control group. Histological ischemia-reperfusion injury was significantly (p < 0.05) more severe in the control group than in the FK group. Serum thromboxane B2 and 6-keto-prostaglandin F1 alpha levels were significantly (p < 0.05) lower in the FK group compared to the control group.
  
  
  CONCLUSIONS
  FK protects the small bowel from ischemia-reperfusion injury by suppression of prostanoid production.
authors.affiliation: Second Department of Surgery, Gunma University School of Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma 371-8511, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kawata
authors.forename: Izumi
authors.initials: I
authors.lastname: Takeyoshi
authors.forename: Kotaro
authors.initials: K
authors.lastname: Iwanami
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sunose
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Tsutsumi
authors.forename: Susumu
authors.initials: S
authors.lastname: Ohwada
authors.forename: Koshi
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishita
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000813:Anilides / Q000494:pharmacology*; D000818:Animals; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000098:blood supply / Q000473:pathology; D007421:Intestine, Small / Q000098:blood supply* / Q000473:pathology; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008641:Mesenteric Vascular Occlusion / Q000473:pathology*; D011292:Premedication; D011451:Prostaglandin-Endoperoxide Synthases; D015427:Reperfusion Injury / Q000473:pathology*; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D000813:Anilides; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; C085566:FK 3311; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases